GlassScriptPhysician profile
Sarah K Min
NPI 1083091466
$477.17
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $132 · 2021: $159.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $117.37 | 2019-2021 | |
| Glaxosmithkline, LLC. | $89.72 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $54.04 | 2019-2020 | |
| Amgen INC. | $51.73 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $44.11 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $26.55 | 2020 | |
| Sanofi Pasteur INC. | $16.23 | 2019 | |
| Phadia US INC. | $14.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.72 | 2021 | |
| Therapeuticsmd, INC. | $13.61 | 2019 | |
| Novo Nordisk INC | $12.20 | 2020 | |
| Genentech USA, INC. | $11.82 | 2020 | |
| Lilly USA, LLC | $11.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.